Mechanisms by which Thiazolidinediones Enhance Insulin Action

作者：Mauricio J. Reginato, Mitchell A. Lazar · 发表于：Trends in Endocrinology and Metabolism · 年份：1999 · DOI：10.1016/s1043-2760(98)00110-6 · 被引用次数：94 · 研究领域：Peroxisome Proliferator-Activated Receptors、Metabolism, Diabetes, and Cancer、Adipose Tissue and Metabolism

Thiazolidinediones (TZDs) are an exciting new class of insulin-sensitizing drugs being used currently for the treatment of non-insulin-dependent diabetes mellitus. The molecular target of these compounds is thought to be the nuclear hormone receptor, peroxisome proliferator-activated receptor gamma (PPARgamma). PPARgamma is expressed predominantly in adipose tissue, yet a major site of TZD-responsive glucose disposal is skeletal muscle. Potential explanations for this paradox are discussed in this review.